Pharmacokinetics and pharmacodynamics of antimicrobial drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 5, 2009, Pages 475-487

  Czock, David ^b   Markert, Christoph ^b   Hartman, Bertram ^a   Keller, Frieder ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Antibiotics; Dose adjustment; Pharmacodynamics; Pharmacokinetics; PK PD modelling

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DAPTOMYCIN; DOXYCYCLINE; HABEKACIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; ORITAVANCIN; PENICILLIN DERIVATIVE; TELITHROMYCIN; TIGECYCLINE; VANCOMYCIN;

AREA UNDER THE CURVE; BACTEREMIA; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; FEBRILE NEUTROPENIA; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OTOTOXICITY; PARAMETER; PHARMACODYNAMICS; PHARMACOKINETIC PHARMACODYNAMIC INDEX; PHARMACOKINETICS; PNEUMONIA; REFERENCE VALUE; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; HUMANS; MODELS, BIOLOGICAL;

ANIMALIA;

EID: 67649360308     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902913808     Document Type: Review

References (82)

1. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793-2797 (Pubitemid 32906673)
2. Ariano RE, Nyhlén A, Donnelly JP, et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005;39:32-38 (Pubitemid 40052375)
3. Bhavnani SM, Passarell JA, Owen JS, et al. Pharmacokinetic- pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006;50:994-1000 (Pubitemid 43327805)
4. Cazzola M, Matera MG, Donnarumma G, et al. Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. Chest 2005;128:2093-2098 (Pubitemid 41507546)
5. Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004;189:1590-1597 (Pubitemid 38648286)
6. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-1081 (Pubitemid 23141323)
7. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999;43:623-629 (Pubitemid 29109529)
8. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007;51:1725-1730 (Pubitemid 46744151)
9. Lodise TP, Preston S, Bhargava V, et al. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagn Microbiol Infect Dis 2005;52:45-52 (Pubitemid 40692739)
10. Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007;51:1939-1945 (Pubitemid 46903077)
11. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004;43:925-942 (Pubitemid 39447034)
12. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-99 (Pubitemid 17225088)
13. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279:125-129 (Pubitemid 28068302)
14. Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003;42:1411-1423 (Pubitemid 38054365)
15. Sato R, Tanigawara Y, Kaku M, et al. Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:3763-3769 (Pubitemid 44684891)
16. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004;2:289-300 •• Review of antimicrobial pharmacokinetics and pharmacodynamics.
17. Czock D, Keller F. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn 2007;34:727-751 (Pubitemid 350165274)
18. Garrod LP. The bactericidal action of streptomycin. Br Med J 1948;1:382-386
19. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108(5 Pt 2):835-840 (Pubitemid 16063283)
20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/; 8 Dec 2008
21. Regoes RR, Wiuff C, Zappala RM, et al. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 2004;48:3670-3676 (Pubitemid 39304588)
22. Grasso S, Meinardi G, de Carneri I, Tamassia V. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother 1978;13:570-576 (Pubitemid 8321200)
23. Blaser J, Stone BB, Zinner SH. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother 1985;27:343-349 (Pubitemid 15144697)
24. Delacher S, Derendorf H, Hollenstein U, et al. A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother 2000;46:733-739 (Pubitemid 30843643)
25. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10 (Pubitemid 28068148)
26. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007;44:79-86 •• Review of antimicrobial pharmacokinetics and pharmacodynamics. (Pubitemid 44968990)
27. Dettli L. The kidney in pre-clinical and clinical pharmacokinetics. Jpn J Clin Pharmacol Ther 1984;15:241-254
28. Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 2008;25:2869-2877
29. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 2003;31:510-518 •• Review of general pharmacodynamics. (Pubitemid 36444157)
30. Goutelle S, Maurin M, Rougier F, et al. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol 2008;22:633-648
31. Czock D, Giehl M. Aminoglycoside pharmacokinetics and -dynamics: a nonlinear approach. Int J Clin Pharmacol Ther 1995;33:537-539
32. Czock D, Giehl M, Keller F. A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: the case of aminoglycosides. Clin Pharmacokinet 2000;38:367-375 (Pubitemid 30229472)
33. Keller F, Aymanns C, Czock D. Pharmacokinetics. In: Offermanns S, Rosenthal W, editors, Encyclopedia of Molecular Pharmacology. 2nd edition Volume1 A-L. Springer, Berlin. 2008. p. 954-960
34. Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005;55:601-607 •• Review of PK-PD terminology for antimicrobial drugs. (Pubitemid 40691835)
35. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002;19:261-268 (Pubitemid 34308974)
36. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003;22:982-992 (Pubitemid 37445077)
37. Zelenitsky S, Ariano R, Harding G, Forrest A. Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. Antimicrob Agents Chemother 2005;49:4009-4014 (Pubitemid 41400939)
38. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007;51:2582-2586 (Pubitemid 47047340)
39. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006;46:1171-1178 (Pubitemid 44387417)
40. Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 2009;53:483-486
41. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52:1330-1336
42. Bouvier d'Yvoire MJY, Maire PH. Dosage regimens of antibacterials. Clin Drug Invest 1996;11:229-239
43. Campion JJ, McNamara PJ, Evans ME. Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:209-219 (Pubitemid 40065795)
44. Campion JJ, Chung P, McNamara PJ, et al. Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:2189-2199 (Pubitemid 40734445)
45. Chung P, McNamara PJ, Campion JJ, Evans ME. Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:2957-2965 (Pubitemid 44396398)
46. Dalla Costa T, Nolting A, Rand K, Derendorf H. Pharmacokinetic- pharmacodynamic modeling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther 1997;35:426-433 (Pubitemid 27462586)
47. De la Pena A, Grabe A, Rand KH, et al. PK-PD modeling of the effect of cefaclor on four different bacterial strains. Int J Antimicrob Agents 2004;23:218-225 (Pubitemid 38283589)
48. Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004;190:1642-1651 (Pubitemid 39411014)
49. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112:275-285 (Pubitemid 38056363)
50. Li RC, Nix DE, Schentag JJ. Pharmacodynamic modeling of bacterial kinetics: beta-lactam antibiotics against Escherichia coli. J Pharm Sci 1994;83:970-975 (Pubitemid 24228547)
51. Lipsitch M, Levin BR. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997;41:363-373 (Pubitemid 27111032)
52. Liu Q, Rand K, Derendorf H. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. Int J Antimicrob Agents 2004;23:494-497 (Pubitemid 38569599)
53. Liu P, Rand KH, Obermann B, Derendorf H. Pharmacokinetic-pharmacodynamic modeling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents 2005;25:120-129 (Pubitemid 40138948)
54. Meagher AK, Forrest A, Dalhoff A, et al. Novel pharmacokinetic- pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob Agents Chemother 2004;48:2061-2068 (Pubitemid 38691598)
55. Mouton JW, Vinks AA, Punt NC. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997;41:733-738 (Pubitemid 27150521)
56. Nielsen EI, Viberg A, Löwdin E, et al. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother 2007;51:128-136 (Pubitemid 46047697)
57. Nolting A, Dalla Costa T, Rand KH, Derendorf H. Pharmacokinetic- pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res 1996;13:91-96 (Pubitemid 26076302)
58. Schuck EL, Dalhoff A, Stass H, Derendorf H. Pharmacokinetic/ pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form. Infection 2005;33(Suppl 2):22-28 (Pubitemid 43151375)
59. Tam VH, Louie A, Deziel MR, et al. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis 2005;192:420-428 (Pubitemid 41023120)
60. Tam VH, Schilling AN, Nikolaou M. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother 2005;55:699-706 (Pubitemid 40691849)
61. Tam VH, Kabbara S, Vo G, et al. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:2626-2631 (Pubitemid 44198680)
62. Tam VH, Schilling AN, Poole K, Nikolaou M. Mathematical modelling response of Pseudomonas aeruginosa to meropenem. J Antimicrob Chemother 2007;60:1302-1309 (Pubitemid 350168327)
63. Tam VH, Ledesma KR, Vo G, et al. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development. Antimicrob Agents Chemother 2008;52:3987-3993
64. Treyaprasert W, Schmidt S, Rand KH, et al. Pharmacokinetic/ pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents 2007;29:263-270 (Pubitemid 46240742)
65. Yano Y, Oguma T, Nagata H, Sasaki S. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci 1998;87:1177-1183 (Pubitemid 28455605)
66. Zhi J, Nightingale CH, Quintiliani R. A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. J Pharm Sci 1986;75:1063-1067 (Pubitemid 17216550)
67. Zhi JG, Nightingale CH, Quintiliani R. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokinet Biopharm 1988;16:355-375 (Pubitemid 18228868)
68. Austin DJ, White NJ, Anderson RM. The dynamics of drug action on the within-host population growth of infectious agents: melding pharmacokinetics with pathogen population dynamics. J Theor Biol 1998;194:313-339 (Pubitemid 28479060)
69. Hoshen MB, Stein WD, Ginsburg HD. Pharmacokinetic-pharmacodynamic modeling of the antimalarial activity of mefloquine. Parasitology 2001;123:337-346 (Pubitemid 32937924)
70. Simpson JA, Watkins ER, Price RN, et al. Mefloquine pharmacokinetic- pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother 2000;44:3414-3424 (Pubitemid 33009503)
71. Gumbo T, Drusano GL, Liu W, et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006;50:3695-3700 (Pubitemid 44684883)
72. Li Y, Nguyen MH, Cheng S, et al. A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. In vitro. Int J Antimicrob Agents 2008;31:369-374
73. Venisse N, Grégoire N, Marliat M, Couet W. Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans. Antimicrob Agents Chemother 2008;52:937-943 (Pubitemid 351358373)
74. Jusko WJ. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci 1971;60:892-895
75. Mattie H. Kinetics of antimicrobial action. Rev Infect Dis 1981;3:19-27
76. Bulitta JB, Ly NS, Yang JC, et al. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53:46-56
77. Drusano GL, Liu W, Brown DL, et al. Impact of short-course quinolone therapy on susceptible and resistant populations of staphylococcus aureus. J Infect Dis 2009;199:219-226
78. Czock D, Rasche FM. Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval? Eur J Med Res 2005;10:145-148
79. Sandiumenge A, Diaz E, Bodí M, Rello J. Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". Intensive Care Med 2003;29:876-883
80. Mueller M, de la Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother 2004;48:369-377 • Review of antimicrobial pharmacokinetics and pharmacodynamics. (Pubitemid 38141689)
81. Mouton JW, Vinks AA. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 2005;44:201-210 (Pubitemid 40188941)
82. Mouton JW, Vinks AA. Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations. Clin Pharmacokinet 2005;44:767-768 (Pubitemid 40994084)